Company / Cash & Equivalents
Atea Pharmaceuticals, Inc. Cash & Equivalents History
FY2020-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$188.5M
FY2022
5-year range
$21.7M / $850.1M
FY2020-FY2022
Trend
-77.8%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $22M to $188M over the past 2 years.
Based on SEC 10-K filings.
$188M in FY2022.
Improved from $22M to $188M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, cash & equivalents decreased 77.8% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 10.30 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $188.5M | -77.8% |
| FY2021 | $850.1M | +3824.6% |
| FY2020 | $21.7M | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026